The anti-cancer activity of TRAIL is attributable to its ability to elicit apoptosis through binding of its functional receptors, death receptors 4 and 5 (DR4 and DR5), and subsequent association with an adaptor protein, Fas-associated death domain (FADD)2. This evidence concerns the gene TNFSF10 and cancer.